The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
Open accessAbstract
BACKGROUND: We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in the development and progression of diabetic retinopathy. METHODS: In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level, <6.0% or 7.0 to 7.9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg). A subgroup of 2856 participants was evaluated for the effects of these interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy. RESULTS: At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycemia treatment, versus 10.4% with standard therapy (adjusted odds ratio, 0.67; 95% confidence interval [CI], 0.51 to 0.87; P=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (adjusted odds ratio, 0.60; 95% CI, 0.42 to 0.87; P=0.006); and 10.4% with intensive blood-pressure therapy, versus 8.8% with standard therapy (adjusted odds ratio, 1.23; 95% CI, 0.84 to 1.79; P=0.29). CONCLUSIONS: Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov numbers, NCT00000620 for the ACCORD study and NCT00542178 for the ACCORD Eye study.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary composite major CV outcomes (nonfatal MI, nonfatal stroke or death from CV causes) were not reduced significantly in ACCORD (hazard ratio [HR] 0.90, p=0.16).”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes, an A1C ≤6.5% may be targeted to reduce the risk of CKD [Grade A, Level 1A (23)] and retinopathy [Grade A, Level 1A (21)], if they are assessed to be at low risk of hypoglycemia based on class of antihyperglycemic medication(s) utilized and the person's characteristics [Grade D, Consensus].”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The UK Prospective Diabetes Study randomly assigned 4209 patients with newly diagnosed type 2 diabetes to receive conventional (primarily diet) vs intensive (insulin, sulfonylurea, or, if overweight, metformin) treatment, with mean attained HbA1C of 7.9% vs 7.0%, respectively.36,37”
From Diagnosis and Treatment of Type 2 Diabetes in Adults (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Other options that can stabilize retinopathy include lifestyle intervention or bariatric surgery in persons with T2D or physical activity in persons with T1D.524–527”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [527]
Experimental — accuracy not yet measuredIn the citing paper
“Fenofibrate reduces the progression of diabetic retinopathy.413,414”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [414]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Davis MD, 1998, Invest Ophthalmol Vis Sci, 39, 233
- Cullen JF, 1964, Trans Ophthalmol Soc U K, 84, 281
- The ACCORD Study Group, 2007, Am J Cardiol, 99, 21i
- Ismail-Beigi F, 2010, Lancet, 375, 26
Cited by
Sorted by citations
Items 101–200 of 1,000
O'Brien, R., Johnson, E., Haneuse, S., Coleman, K. J., O'Connor, P. J., Fisher, D. P., Sidney, S., Bogart, A., Theis, M. K., Anau, J., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2383 · Cited by 161
Renin‐Angiotensin‐Aldosterone System in Diabetes and Hypertension
Hsueh, W. A., & Wyne, K. L. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00449.x · Cited by 166
Feldman-Billard, S., Larger, É., & Massin, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.10.014 · Cited by 169
Does microvascular disease predict macrovascular events in type 2 diabetes?
Rosenson, R. S., Fioretto, P., & Dodson, P. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.029 · Cited by 162
Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy
Sabanayagam, C., Yip, W., Ting, D. S. W., Tan, G. S. W., & Wong, T. Y. (2016) · Ophthalmic Epidemiology · doi:10.1080/09286586.2016.1193618 · Cited by 164
Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes
Nair, A. T. N., Wesolowska‐Andersen, A., Brorsson, C., Rajendrakumar, A. L., Hapca, S. M., Gan, S., Dawed, A. Y., Donnelly, L. A., McCrimmon, R. J., Doney, A. S. F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01790-7 · Cited by 169
Zhang, J., Cheng, Y., Gu, J., Wang, S., Zhou, S., Wang, Y., Tan, Y., Feng, W., Fu, Y., Mellen, N. M., et al. (2016) · Clinical Science · doi:10.1042/cs20150623 · Cited by 161
Serum triglycerides and risk of cardiovascular disease
Boullart, A. C. I., Graaf, J. D., & Stalenhoef, A. F. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.002 · Cited by 159
Angiopoietin 2 Induces Pericyte Apoptosis via α3β1 Integrin Signaling in Diabetic Retinopathy
Park, S. W., Yun, J.-H., Kim, J. H., Kim, K.-W., Cho, C., & Kim, J. H. (2014) · Diabetes · doi:10.2337/db13-1942 · Cited by 157
Reiner, Ž. (2013) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.05.002 · Cited by 147
Differential Association of Serum Lipids with Diabetic Retinopathy and Diabetic Macular Edema
Benarous, R., Sasongko, M. B., Qureshi, S. H., Fenwick, E., Dirani, M., Wong, T. Y., & Lamoureux, E. L. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7598 · Cited by 152
The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
Avogaro, A., & Fadini, G. P. (2014) · Diabetes Care · doi:10.2337/dc14-0865 · Cited by 154
Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPARα
Chen, Q., Qiu, F., Zhou, K., Matlock, H. G., Takahashi, Y., Rajala, R. V. S., Yang, Y., Pearsall, E., & Ma, J. (2017) · Diabetes · doi:10.2337/db16-1246 · Cited by 152
von Eckardstein, A., & Sibler, R. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283412279 · Cited by 151
Ischemic Retinopathies: Oxidative Stress and Inflammation
Rivera, J. C., Dabouz, R., Noueihed, B., Omri, S., Tahiri, H., & Chemtob, S. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3940241 · Cited by 153
Diabetic retinopathy for the non-ophthalmologist
Fung, T. H., Patel, B., Wilmot, E. G., & Amoaku, W. M. (2022) · Clinical Medicine · doi:10.7861/clinmed.2021-0792 · Cited by 151
Fibrates for primary prevention of cardiovascular disease events
Jakob, T., Nordmann, A. J., Schandelmaier, S., Ferreira-González, I., & Briel, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009753.pub2 · Cited by 147
Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141
Diagnosis and Treatment of Type 2 Diabetes in Adults
Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J. (2025) · JAMA · doi:10.1001/jama.2025.5956 · Cited by 145
Cheung, C. Y.-L., Ikram, M. K., Klein, R., & Wong, T. Y. (2015) · Diabetologia · doi:10.1007/s00125-015-3511-1 · Cited by 144
Nazir, S., Jankowski, V., Bender, G., Zewinger, S., Rye, K.-A., & van der Vorst, E. P. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.006 · Cited by 140
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Pathak, R. D., Schroeder, E. B., Seaquist, E. R., Zeng, C., Lafata, J. E., Thomas, A., Desai, J., Waitzfelder, B., Nichols, G. A., Lawrence, J. M., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0858 · Cited by 140
Wu, Y. H., Tang, L., & Chen, B. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/752387 · Cited by 143
Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment
Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.133 · Cited by 142
Averna, M. R., Banach, M., Bruckert, É., Drexel, H., Farnier, M., Gaiță, D. I., Magni, P., März, W., Masana, L., Silva, A. M. E., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.039 · Cited by 143
How to Use an Article About Quality Improvement
Fan, E., Laupacis, A., Pronovost, P. J., Guyatt, G. H., & Needham, D. M. (2010) · JAMA · doi:10.1001/jama.2010.1692 · Cited by 137
Autophagy in Diabetic Retinopathy
Rosa, M. D., Distefano, G., Gagliano, C., Rusciano, D., & Malaguarnera, L. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160321122900 · Cited by 137
Vitamin D Insufficiency in Diabetic Retinopathy
Payne, J. F., Ray, R., Watson, D. G., Lahiri, C. D., Rimler, E., Cleveland, J., Lynn, M., Tangpricha, V., & Srivastava, S. K. (2011) · Endocrine Practice · doi:10.4158/ep11147.or · Cited by 138
Diabetes microvascular complications—A clinical update
Khalil, H. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.022 · Cited by 147
Intensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial
Schwartz, A. V., Margolis, K. L., Sellmeyer, D. E., Vittinghoff, E., Ambrosius, W. T., Bonds, D. E., Josse, R. G., Schnall, A. M., Simmons, D. L., Hue, T. F., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2184 · Cited by 131
Predicting Development of Proliferative Diabetic Retinopathy
Nwanyanwu, K. H., Talwar, N., Gardner, T. W., Wrobel, J. S., Herman, W. H., & Stein, J. D. (2012) · Diabetes Care · doi:10.2337/dc12-0790 · Cited by 131
Qiu, F., Meng, T., Chen, Q., Zhou, K., Shao, Y. X., Greg, M. H., Ma, X., Wu, W., Du, Y., Wang, X., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01319 · Cited by 135
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.016 · Cited by 130
9. Microvascular Complications and Foot Care
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s012 · Cited by 136
Low HDL Cholesterol and the Risk of Diabetic Nephropathy and Retinopathy
Morton, J., Zoungas, S., Li, Q., Patel, A. A., Chalmers, J. P., Woodward, M., Celermajer, D. S., Beulens, J. W. J., Stolk, R. P., Glasziou, P., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0306 · Cited by 127
Blood pressure control for diabetic retinopathy
Diana, V., Wang, X., Vedula, S. S., Marrone, M. T., Sleilati, G. G., Hawkins, B. S., & Frank, R. N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006127.pub2 · Cited by 138
Plasma Metabonomic Profiling of Diabetic Retinopathy
Chen, L., Cheng, C., Choi, H., Ikram, M. K., Sabanayagam, C., Tan, G. S. W., Tian, D., Zhang, L., Venkatesan, G., Tai, E. S., et al. (2016) · Diabetes · doi:10.2337/db15-0661 · Cited by 128
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Epidemiology of diabetic retinopathy and maculopathy in Africa: a systematic review
Burgess, P. I., MacCormick, I. J. C., Harding, S. P., Bastawrous, A., Beare, N. A. V., & Garner, P. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03756.x · Cited by 130
Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis
Wang, B., Wang, F., Zhang, Y., Zhao, S.-H., Zhao, W., Yan, S., & Wang, Y. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70256-6 · Cited by 131
Choroid Sprouting Assay: An Ex Vivo Model of Microvascular Angiogenesis
Shao, Z., Friedlander, M. S. H., Hurst, C. G., Cui, Z., Pei, D. T., Evans, L. P., Juan, A. M., Tahir, H., Duhamel, F., Chen, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069552 · Cited by 125
9. Microvascular Complications and Foot Care
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s012 · Cited by 124
Gustavsson, C., Agardh, C., Zetterqvist, A. V., Nilsson, J. Å., Agardh, E., & Gomez, M. F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012699 · Cited by 125
Diabetic retinopathy: Screening, prevention, and treatment
Chong, D. D., Das, N., & Singh, R. P. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.24028 · Cited by 140
Noonan, J. E., Jenkins, A. J., Ma, J., KEECH, A. C., Wang, J. J., & Lamoureux, E. L. (2013) · Diabetes · doi:10.2337/db13-0800 · Cited by 120
Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial
Gerstein, H. C., Ambrosius, W. T., Danis, R. P., Ismail‐Beigi, F., Cushman, W. C., Calles, J., Banerji, M., Schubart, U. K., Chew, E. Y., & for the ACCORD Study Group (2012) · Diabetes Care · doi:10.2337/dc12-1311 · Cited by 119
Diabetic Retinopathy (DR): Mechanisms, Current Therapies, and Emerging Strategies
Seo, H., Park, S.-J., & Song, M. (2025) · Cells · doi:10.3390/cells14050376 · Cited by 119
Dyslipidemia and Diabetic Retinopathy
Chang, Y., & Wu, W. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.121 · Cited by 117
Demystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Choroidal Thinning in Diabetes Type 1 Detected by 3-Dimensional 1060 nm Optical Coherence Tomography
Esmaeelpour, M., Brunner, S. F., Ansari‐Shahrezaei, S., Nemetz, S., Považay, B., Kajic, V., Drexler, W., & Binder, S. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10314 · Cited by 114
Imran, S. A., Agarwal, G., Bajaj, H. S., & Ross, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.030 · Cited by 113
Glucose targets for preventing diabetic kidney disease and its progression
Ruospo, M., Saglimbene, V. M., Palmer, S. C., De Cosmo, S., Pacilli, A., Lamacchia, O., Cignarelli, M., Fioretto, P., Vecchio, M., Craig, J. C., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010137.pub2 · Cited by 111
Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy
Kang, E. Y., Chen, T., Garg, S. J., Sun, C., Kang, J., Wu, W., Hung, M., Lai, C., Cherng, W., & Hwang, Y. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6399 · Cited by 112
Diabetic Retinopathy: The Role of Mitochondria in the Neural Retina and Microvascular Disease
Miller, D. J., Cascio, M. A., & Rosca, M. G. (2020) · Antioxidants · doi:10.3390/antiox9100905 · Cited by 116
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Callaghan, B. C., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s012 · Cited by 160
Challenges in Elucidating the Genetics of Diabetic Retinopathy
Kuo, J. Z.-C., Wong, T. Y., & Rotter, J. I. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.5024 · Cited by 111
Epidemiological issues in diabetic retinopathy
Scanlon, P. H., Aldington, S. J., & STRATTON, I. M. (2013) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.120007 · Cited by 115
INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA
Yang, Y. C., Bailey, C., Loewenstein, A., & Massin, P. (2015) · Retina · doi:10.1097/iae.0000000000000726 · Cited by 106
Moltó, A., Medina, C. L., den Bosch, F. E. V., Boonen, A. E. R. C. H., Webers, C., Dernis, E., van Gaalen, F. A., Soubrier, M., Claudepierre, P., Baillet, A. C., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219585 · Cited by 107
Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy
Tomita, Y., Lee, D., Tsubota, K., Negishi, K., & Kurihara, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204666 · Cited by 116
Management Paradigms for Diabetic Macular Edema
Mitchell, P., & Wong, T. Y. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.11.012 · Cited by 103
(2023) · doi:10.1002/14651858.cd013775.pub2 · Cited by 145
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 157
[WITHDRAWN] Retinal Vasculature in Development and Diseases
Sun, Y., & Smith, L. E. H. (2018) · Annual Review of Vision Science · doi:10.1146/annurev-vision-091517-034018 · Cited by 106
RetractedRelationships Between Neurodegeneration and Vascular Damage in Diabetic Retinopathy
Rossino, M. G., Monte, M. D., & Casini, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01172 · Cited by 104
Fenofibrate – A Potential Systemic Treatment for Diabetic Retinopathy?
Wong, T. Y., Simó, R., & Mitchell, P. L. R. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.013 · Cited by 100
Diabetic retinopathy management guidelines
Chakrabarti, R., Harper, C. A., & Keeffe, J. E. (2012) · Expert Review of Ophthalmology · doi:10.1586/eop.12.52 · Cited by 112
Hill, M. D. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00012-6 · Cited by 108
Watts, G. F., & Karpe, F. (2011) · Heart · doi:10.1136/hrt.2010.204990 · Cited by 97
The role of dyslipidemia in diabetic retinopathy
Hammer, S. S., & Busik, J. V. (2017) · Vision Research · doi:10.1016/j.visres.2017.04.010 · Cited by 100
Ferrari, R., Aguíar, C., Alegría, E., Bonadonna, R. C., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hâncu, N., et al. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw009 · Cited by 97
Song, K., Jeong, J., Kim, M. K., Kwon, H., Baek, K., Ko, S., & Ahn, Y. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12953 · Cited by 99
Selvachandran, G., Quek, S. G., Paramesran, R., Ding, W., & Sơn, L. H. (2022) · Artificial Intelligence Review · doi:10.1007/s10462-022-10185-6 · Cited by 99
Current Treatments for Diabetic Macular Edema
Tatsumi, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119591 · Cited by 107
Chen, Y., Chen, H.-S., & Tarng, D. (2012) · Diabetes Care · doi:10.2337/dc11-1955 · Cited by 102
Fatty acid oxidation and photoreceptor metabolic needs
Fu, Z., Kern, T. S., Hellström, A., & Smith, L. E. H. (2020) · Journal of Lipid Research · doi:10.1194/jlr.tr120000618 · Cited by 98
The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders
Menini, S., Iacobini, C., Vitale, M., & Pugliese, G. (2020) · Cells · doi:10.3390/cells9081812 · Cited by 97
The Effect of Diet and Lifestyle on the Course of Diabetic Retinopathy—A Review of the Literature
Bryl, A., Mrugacz, M., Falkowski, M., & Zorena, K. (2022) · Nutrients · doi:10.3390/nu14061252 · Cited by 98
Liu, Q., Zhang, F., Zhang, X., Cheng, R., Ma, J., Yi, J., & Li, J. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3256-x · Cited by 94
Effect of Fenofibrate on Progression of Diabetic Retinopathy
Preiss, D., Logue, J., Sammons, E. L., Zayed, M., Emberson, J., Wade, R. L., Wallendszus, K., Stevens, W., Cretney, R., Harding, S. P., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2400179 · Cited by 94
The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
Toth, P. P., Simko, R. J., Palli, S. R., Koselleck, D., Quimbo, R. A., & Cziraky, M. J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-109 · Cited by 93
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Dyslipidemia in retinal metabolic disorders
Fu, Z., Chen, C. T., Cagnone, G., Heckel, É., Sun, Y., Cakir, B., Tomita, Y., Huang, S., Li, Q., Britton, W. R., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910473 · Cited by 92
Peroxisome Proliferator–Activated Receptor α Protects Capillary Pericytes in the Retina
Ding, L., Cheng, R., Hu, Y., Takahashi, Y., Jenkins, A. J., KEECH, A. C., Humphries, K. M., Gu, X., Elliott, M. H., Xia, X., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.06.021 · Cited by 93
Royle, P., Mistry, H., Auguste, P., Shyangdan, D., Freeman, K., Lois, N., & Waugh, N. R. (2015) · Health Technology Assessment · doi:10.3310/hta19510 · Cited by 96
Klein, R., Myers, C. E., Howard, K. P., & Klein, R. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.5108 · Cited by 91
First-line treatment algorithm and guidelines in center-involving diabetic macular edema
Kodjikian, L., Bellocq, D., Bandello, F. M., Loewenstein, A., Chakravarthy, U., Koh, A., Augustin, A. J., de Smet, M. D., Chhablani, J. K., Tufail, A., et al. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119857511 · Cited by 91
Islam, K. N., Islam, R. K., Nguyen, I. D., Malik, H., Pirzadah, H., Shrestha, B., Lentz, I. B., Shekoohi, S., & Kaye, A. D. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03185-9 · Cited by 117
Keating, G. M. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11207690-000000000-00000 · Cited by 90
Murad, M. H., Hazem, A., Coto-Yglesias, F., Dzyubak, S., Gupta, S., Bancos, I., Lane, M. A., Erwin, P. J., Berglund, L., Elraiyah, T., et al. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-2 · Cited by 87
Kowluru, R. A., Mishra, M., Kowluru, A., & Kumar, B. (2016) · Metabolism · doi:10.1016/j.metabol.2016.07.012 · Cited by 89
Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus
Tandon, N., Ali, M. K., & Narayan, K. M. V. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11594650-000000000-00000 · Cited by 88
Rao, H., Jalali, J. A., Johnston, T. P., & Koulen, P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.620045 · Cited by 89
Das, T., Takkar, B., Sivaprasad, S., Thanksphon, T., Taylor, H. R., Wiedemann, P., Németh, J., Nayar, P. D., Rani, P. K., & Khandekar, R. B. (2021) · Eye · doi:10.1038/s41433-021-01572-4 · Cited by 85
Shrikhande, G., Scali, S. T., da Silva, C. G., Damrauer, S. M., Csizmadia, E., Putheti, P., Matthey, M., Arjoon, R., Patel, R., Siracuse, J. J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014240 · Cited by 89
The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus
Elam, M. B., Lovato, L., & Ginsberg, H. N. (2011) · Clinical Lipidology · doi:10.2217/clp.10.84 · Cited by 88
Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic
Burgess, P. I., Msukwa, G., & Beare, N. A. V. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-157 · Cited by 86
Aguíar, C., Alegría, E., Bonadonna, R. C., Catapano, A. L., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hâncu, N., et al. (2015) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(15)30001-5 · Cited by 84
Chung, Y.-R., Park, S. W., Choi, S.-Y., Kim, S. W., Moon, K. Y., Kim, J. H., & Lee, K. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0486-2 · Cited by 84
Metadata
- Authors
- The ACCORD Study Group and ACCORD Eye Study Group
- Corresponding author
- The ACCORD Study Group and ACCORD Eye Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-15
- Volume
- 363
- Issue
- 3
- Pages
- 233-244
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4026164
- OpenAlex
- W2219384223
- Semantic Scholar
- 9a607a3bfd9432a917f703d573fdaa1052647711
- Cited by
- 1,311
- References
- 36
- Citations by year
- 2026: 54 · 2025: 60 · 2024: 66 · 2023: 86 · 2022: 73 · 2021: 94 · 2020: 96 · 2019: 57 · 2018: 78 · 2017: 87 · 2016: 82 · 2015: 84 · 2014: 74 · 2013: 81 · 2012: 93
- FWCI
- 111.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Massachusetts Medical Society
- Omron Healthcare
- Bayer HealthCare
- Daiichi-Sankyo
- Novo Nordisk
- Servier
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, Z99 EY999999, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Heart, Lung, and Blood Institute (N01- HC-95181, R01HL073030, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Eye Institute (ZIAEY000410)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic retinopathy, retinopathy progression, type 2 diabetes, tight glycemic control, HbA1c, fenofibrate, simvastatin, dyslipidemia, blood pressure control, laser photocoagulation, vitrectomy, cardiovascular risk reduction, combination therapy, Early Treatment Diabetic Retinopathy Study
- MeSH terms
- Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Drug Therapy, Combination, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypertension, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Fenofibrate, Disease Progression, Simvastatin, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
